BIOMAT Database Logo BIOMAT Database Logo

Evaluation of serum tumor markers in patients with advanced or recurrent breast cancer. 1995

H Iwase, and S Kobayashi, and Y Itoh, and H Fukuoka, and T Kuzushima, and H Iwata, and T Yamashita, and A Naitoh, and K Itoh, and A Masaoka
Second Department of Surgery, Nagoya City University Medical School, Japan.

Serum CA15-3, CEA, and BCA225 concentrations were determined in 98 patients with advanced or recurrent breast cancer in an attempt to correlate elevation with clinical status. The rate of serum positivity was 68.4% (67/98), 55.1% (54/98), and 43.9% (43/98) for CA15-3, CEA, and BCA225, respectively. After a 4 weeks-interval, a 20% change of tumor marker concentration from the preceding assay correlated significantly with clinical findings. Significant elevation was predictive of new recurrence or tumor regrowth after complete remission, especially in patients with bone metastasis. The 20% change in concentration at 4 weeks was also useful in patients with tumor marker concentrations persistently beneath the cut-off level for positive. Serological evaluation of tumor markers in patients with advanced or recurrent breast cancer should seek to document 20% changes over a 4 week interval.

UI MeSH Term Description Entries
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002272 Carcinoembryonic Antigen A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment. Antigens, CD66e,CD66e Antigen,Antigen, CD66e,Antigen, Carcinoembryonic,CD66e Antigens
D006023 Glycoproteins Conjugated protein-carbohydrate compounds including MUCINS; mucoid, and AMYLOID glycoproteins. C-Glycosylated Proteins,Glycosylated Protein,Glycosylated Proteins,N-Glycosylated Proteins,O-Glycosylated Proteins,Glycoprotein,Neoglycoproteins,Protein, Glycosylated,Proteins, C-Glycosylated,Proteins, Glycosylated,Proteins, N-Glycosylated,Proteins, O-Glycosylated
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D018396 Mucin-1 Carbohydrate antigen elevated in patients with tumors of the breast, ovary, lung, and prostate as well as other disorders. The mucin is expressed normally by most glandular epithelia but shows particularly increased expression in the breast at lactation and in malignancy. It is thus an established serum marker for breast cancer. Antigen CA-15-3,CA-15-3 Antigen,Episialin,Epithelial Membrane Antigen,Epithelial Mucin, Polymorphic,Muc1 Mucin,Polymorphic Epithelial Mucin,Antigens, CD227,CA 15-3 Antigen,CA 15.3 Antigen,CD227 Antigen,Antigen CA 15 3,Antigen, CA 15-3,Antigen, CA 15.3,Antigen, CA-15-3,Antigen, CD227,Antigen, Epithelial Membrane,CA 15 3 Antigen,CA-15-3, Antigen,CD227 Antigens,Membrane Antigen, Epithelial,Mucin 1,Mucin, Muc1,Mucin, Polymorphic Epithelial

Related Publications

H Iwase, and S Kobayashi, and Y Itoh, and H Fukuoka, and T Kuzushima, and H Iwata, and T Yamashita, and A Naitoh, and K Itoh, and A Masaoka
Serum tumor markers in patients with breast cancer.
October 2004, Expert review of anticancer therapy,
H Iwase, and S Kobayashi, and Y Itoh, and H Fukuoka, and T Kuzushima, and H Iwata, and T Yamashita, and A Naitoh, and K Itoh, and A Masaoka
Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers.
June 2002, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR),
H Iwase, and S Kobayashi, and Y Itoh, and H Fukuoka, and T Kuzushima, and H Iwata, and T Yamashita, and A Naitoh, and K Itoh, and A Masaoka
[Clinical evaluation of tumor markers in breast cancer patients].
October 1987, Gan to kagaku ryoho. Cancer & chemotherapy,
H Iwase, and S Kobayashi, and Y Itoh, and H Fukuoka, and T Kuzushima, and H Iwata, and T Yamashita, and A Naitoh, and K Itoh, and A Masaoka
Significance of serum tumor markers in monitoring advanced breast cancer patients treated with systemic therapy: a prospective study.
January 2004, Breast cancer (Tokyo, Japan),
H Iwase, and S Kobayashi, and Y Itoh, and H Fukuoka, and T Kuzushima, and H Iwata, and T Yamashita, and A Naitoh, and K Itoh, and A Masaoka
[Clinical evaluation of adriamycin ointment in advanced or local recurrent breast cancer].
March 1986, Gan to kagaku ryoho. Cancer & chemotherapy,
H Iwase, and S Kobayashi, and Y Itoh, and H Fukuoka, and T Kuzushima, and H Iwata, and T Yamashita, and A Naitoh, and K Itoh, and A Masaoka
Tumor markers in patients with advanced breast cancer as prognosticators: a preliminary study.
January 1994, Breast cancer research and treatment,
H Iwase, and S Kobayashi, and Y Itoh, and H Fukuoka, and T Kuzushima, and H Iwata, and T Yamashita, and A Naitoh, and K Itoh, and A Masaoka
Evaluation of tumor markers in southern Indian breast cancer patients.
January 2010, Asian Pacific journal of cancer prevention : APJCP,
H Iwase, and S Kobayashi, and Y Itoh, and H Fukuoka, and T Kuzushima, and H Iwata, and T Yamashita, and A Naitoh, and K Itoh, and A Masaoka
Benefits of Medroxyprogesterone Acetate (MPA) in Advanced or Recurrent Breast Cancer with Higher Serum Concertration.
October 1995, Breast cancer (Tokyo, Japan),
H Iwase, and S Kobayashi, and Y Itoh, and H Fukuoka, and T Kuzushima, and H Iwata, and T Yamashita, and A Naitoh, and K Itoh, and A Masaoka
Evaluation of prognostic factors for 233 patients with recurrent advanced breast cancer.
October 1991, Japanese journal of clinical oncology,
H Iwase, and S Kobayashi, and Y Itoh, and H Fukuoka, and T Kuzushima, and H Iwata, and T Yamashita, and A Naitoh, and K Itoh, and A Masaoka
Association between serum tumor markers and metabolic tumor volume or total lesion glycolysis in patients with recurrent small cell lung cancer.
November 2015, Oncology letters,
Copied contents to your clipboard!